Thursday, 15 October 2026European Markets

SCANA Stock Rises By 21% In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of SCANA (Oslo Børs Benchmark Index_GI: SCANA.OL) rose by a staggering 21.91% in 10 sessions from kr1.3 to kr1.58 at 14:39 EST on Thursday, after three sequential sessions in a row of gains. Oslo Børs Benchmark Index_GI is falling 0.02% to kr1,215.44, after two consecutive sessions in a row of gains.

SCANA's last close was kr1.54, 14.13% under its 52-week high of kr1.80.

About SCANA

Scana ASA provides equipment and services to the maritime industry. The company offers valve remote control systems and mooring solutions to vessels, rigs, and floating structures serving the shipping, oil and gas, aquaculture, and energy industries. It also engages in the design and integration of electrical power systems, electrical infrastructure, and energy storage systems and control systems; and provides standard and customized containers/module solutions, as well as various types of welded constructions for offshore and onshore projects. In addition, the company is involved in the planning and execution of insulation, scaffolding, and surface treatment services; and rig, capping, equipment support, make and break, IMR lifecycle, welding, and asset integrity management services to drilling industry, as well as offers riser applications to the oil and gas industry. The company was formerly known as Incus Investor ASA and changed its name to Scana ASA in May 2020. Scana ASA was founded in 1646 and is headquartered in Bergen, Norway.

Earnings Per Share

As for profitability, SCANA has a trailing twelve months EPS of kr0.09.

PE Ratio

SCANA has a trailing twelve months price to earnings ratio of 17.51. Meaning, the purchaser of the share is investing kr17.51 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -14.97%.

More news about SCANA (SCANA.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com